Hospitals get much higher reimbursements from commercial payers than they do from Part B , so 340B margins are likely also higher.Hospitals and their lobbyists loudly and frequently tout the falsehood that the 340B Drug Pricing Program amounts to “only 2%” of total U.S. drug purchases.